NOVN.VX - Novartis AG

Swiss - Swiss Delayed price. Currency in CHF
80.80
+1.18 (+1.48%)
At close: 5:30PM CET
Stock chart is not supported by your current browser
Previous close79.62
Open80.00
Bid77.50 x 373700
Ask78.60 x 1281100
Day's range79.48 - 80.80
52-week range72.45 - 88.30
Volume7,684,652
Avg. volume5,024,537
Market cap187.251B
BetaN/A
PE ratio (TTM)24.86
EPS (TTM)3.25
Earnings date19 Apr 2018
Forward dividend & yield2.57 (3.64%)
Ex-dividend date2017-03-02
1y target est95.32
  • Reutersyesterday

    Novartis readies to auction U.S. generic pills business - sources

    The move illustrates how the unit has diverged from the fortunes of the rest of Novartis' $10 billion (7.12 billion pounds) Sandoz generics and biosimilars division. The company has fared better in manufacturing hard-to-make generic drugs, such as injectables and inhalables, than it has with easier to produce pills. "It is a unique situation," new Novartis Chief Executive Vasant Narasimhan told investors and analysts during the company's fourth-quarter earnings call last month when asked about the future of the U.S. generic pills business.

  • 3 Tough Questions for Amgen
    Motley Fool3 days ago

    3 Tough Questions for Amgen

    How successful will Amgen be in the future? Its answers to these three questions provide insight.

  • Reuters4 days ago

    Novartis gains U.S. approval for delayed MS drug

    Novartis's (NOVN.S) Sandoz division has won U.S. approval for a larger dosage of its Glatopa drug for multiple sclerosis (MS) patients, ending a costly delay that allowed rival generics makers to beat it to market. The U.S. Food and Drug Administration (FDA) approved a 40 milligrams per millilitre injection of the Novartis copy of Copaxone, Teva's (TEVA.N)(TEVA.TA) blockbuster medicine, Sandoz said in a statement on Tuesday. Israel-based Teva Pharmaceutical Industries began facing competition for its 40 mg version of Copaxone from Mylan (MYL.O) in October and has been bracing for more copycat versions of its bestselling drug.

  • MarketWatch4 days ago

    Teva shares drop 3% after rival generic product approved and launched

    Teva Pharmaceutical Industries Ltd. shares dropped 3% in premarket trade Tuesday after Novartis AG's Sandoz announced that the 40 mg dose of Glatopa, its generic for Teva's popular multiple sclerosis medication ...

  • Reuters - UK Focus4 days ago

    Novartis gains U.S. approval for delayed MS drug

    Novartis (IOB: 0QLR.IL - news) 's Sandoz division has won U.S. approval for a larger dosage of its Glatopa drug for multiple sclerosis (MS) patients, ending a costly delay that allowed rival generics makers to beat it to market. The U.S. Food and Drug Administration (FDA) approved a 40 milligrams per millilitre injection of the Novartis copy of Copaxone, Teva's blockbuster medicine, Sandoz said in a statement on Tuesday.

  • Regeneron Could Benefit From 'Lackluster' Data Presented By These Rivals
    Investor's Business Daily5 days ago

    Regeneron Could Benefit From 'Lackluster' Data Presented By These Rivals

    Regeneron should benefit after Novartis and Roche presented data for competitors to blockbuster eye drug Eylea. 

  • Greek PM wants politicians investigated in alleged Novartis bribery case
    Reuters5 days ago

    Greek PM wants politicians investigated in alleged Novartis bribery case

    ATHENS/ZURICH (Reuters) - Greece's prime minister urged parliament on Monday to probe politicians in an alleged drug bribery case, while Swiss drugmaker Novartis (NOVN.S) promised to take action if an investigation found unethical conduct. Novartis (NOVN.S) said it would take "fast and decisive action" should an investigation into alleged bribery in Greece find that its managers engaged in unethical or illegal conduct. Greece's Prime Minister Alexis Tsipras on Monday urged parliament to investigate the case.

  • Reuters5 days ago

    Greek PM wants politicians investigated in alleged Novartis bribery case

    ATHENS/ZURICH (Reuters) - Greece's prime minister urged parliament on Monday to probe politicians in an alleged drug bribery case, while Swiss drugmaker Novartis (NOVN.S) promised to take action if an investigation found unethical conduct. Novartis (NOVN.S) said it would take "fast and decisive action" should an investigation into alleged bribery in Greece find that its managers engaged in unethical or illegal conduct. Greece's Prime Minister Alexis Tsipras on Monday urged parliament to investigate the case.

  • Forbes5 days ago

    How Much Profit Should Novartis Earn By Curing A Childhood Leukemia?

    Putting artificial caps on profitability for drugs that add real value to patients is not the answer.

  • The Wall Street Journal8 days ago

    [$$] Novartis Faces Investigation For Alleged Bribery In Greece

    Pharmaceutical giant Novartis has come under investigation in Greece on allegations that the Swiss group bribed officials and doctors to fix drug prices and boost its sales to public hospitals.

  • The Zacks Analyst Blog Highlights: Novartis, BP and Biogen
    Zacks8 days ago

    The Zacks Analyst Blog Highlights: Novartis, BP and Biogen

    The Zacks Analyst Blog Highlights: Novartis, BP and Biogen

  • Top Research Reports for Novartis, BP & Biogen
    Zacks9 days ago

    Top Research Reports for Novartis, BP & Biogen

    Top Research Reports for Novartis, BP & Biogen

  • Novartis' Cosentyx Label Expanded to Include Scalp Psoriasis
    Zacks9 days ago

    Novartis' Cosentyx Label Expanded to Include Scalp Psoriasis

    Novartis' (NVS) psoriasis drug, Cosentyx is already approved for the treatment of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis.

  • Forbes9 days ago

    Patient Advocate Says Novartis' $475,000 Breakthrough Should Cost Just $160,000

    David Mitchell, 67, says he’s sure that Novartis’ Kymriah is a breakthrough medicine, and that he will need a similar medicine to treat his own blood cancer. He’s sure of something else, too: Novartis is charging too much.

  • Glaxo's Key Drug Gains Time as FDA Denies Novartis Generic
    Bloomberg10 days ago

    Glaxo's Key Drug Gains Time as FDA Denies Novartis Generic

    GlaxoSmithKline Plc’s asthma drug Advair won some room to run as U.S. regulators denied approval to rival Novartis AG’s generic version of the blockbuster treatment.

  • Reuters - UK Focus10 days ago

    Drugmaker GSK wins fresh Advair reprieve as Novartis copy delayed

    GlaxoSmithKline (Other OTC: GLAXF - news) has won another reprieve for its blockbuster Advair lung drug after U.S. regulators delayed approval of a generic copy from Novartis's Sandoz division. The Swiss drugmaker said in an emailed statement on Thursday it had received a so-called complete response letter from the U.S. Food and Drug Administration (FDA) and a generic Advair launch this year was now "highly unlikely".

  • Associated Press12 days ago

    Greek govt alleges official ties to drug bribery scandal

    ATHENS, Greece (AP) — Greece's government said Monday it has been handed evidence that senior politicians from the previous administration were involved in a bribery case in which Swiss drugmaker Novartis is accused of making illegal payments to fix prices and increase market access.

  • Bloomberg17 days ago

    Stada Names Sandoz Manager as Fifth CEO Since 2016

    Stada Arzneimittel AG will get its fifth chief executive officer in a little over two years as the German maker of copycat pills taps a Novartis AG manager to take over from Claudio Albrecht, who was brought ...

  • Novartis' Lutathera Gets FDA Approval for Pancreatic Tumors
    Zacks19 days ago

    Novartis' Lutathera Gets FDA Approval for Pancreatic Tumors

    Novartis' oncology portfolio gets a further boost with the FDA approval of Lutathera for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors.

  • Foreign Stock Roundup: Novartis, UBS & Posco Results Impress, Sanofi Buys Bioverativ
    Zacks19 days ago

    Foreign Stock Roundup: Novartis, UBS & Posco Results Impress, Sanofi Buys Bioverativ

    The government shutdown in the United States guided stocks across Europe and Asia last week.

  • Globe Newswire22 days ago

    Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors

    Lutathera marks first FDA Approval for a Peptide Receptor Radionuclide Therapy (PRRT)   Advanced Accelerator Applications is a newly established subsidiary of Novartis   Lutathera expands Novartis' neuroendocrine tumor portfolio, building on long heritage and leadership

  • Novartis Gets Spark Therapeutics' Luxterna License Outside US
    Zacks22 days ago

    Novartis Gets Spark Therapeutics' Luxterna License Outside US

    Novartis has obtained the marketing rights for Luxterna oustide the United States thereby building upon its gene therapy treatments which includes Kymriah.

  • Reuters24 days ago

    Spark licenses blindness gene therapy rights outside U.S. to Novartis

    Philadelphia-based Spark said it will keep U.S. rights to Luxturna, or voretigene neparvovec, which is the first approved gene therapy for an inherited disease. It plans to launch the one-time treatment in March, charging an unprecedented $850,000.

  • Globe Newswire24 days ago

    Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision loss

    Novartis enters into a licensing and supply agreement to develop, register and commercialize investigational gene therapy voretigene neparvovec outside the US; Spark Therapeutics retains US rights for LUXTURNA(TM) (voretigene neparvovec-rzyl)   Voretigene neparvovec is an investigational one-time gene therapy to restore functional vision for patients with biallelic mutations of the RPE65 gene  This investigational therapy provides patients with a working copy of the RPE65 gene to treat otherwise progressive vision loss that typically leads to blindness

  • Globe Newswire24 days ago

    Spark Therapeutics Enters into a Licensing and Supply Agreement for Investigational Voretigene Neparvovec Outside the U.S.

    Spark Therapeutics to receive $105 million as an upfront fee and is eligible to receive up to $65 million in milestone payments, as well as receive a royalty on net sales outside the U.S. PHILADELPHIA, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced it has entered into a licensing agreement with Novartis Pharmaceuticals to develop and commercialize investigational voretigene neparvovec outside the U.S., while Spark Therapeutics will continue to exclusively commercialize LUXTURNA™ (voretigene neparvovec-ryzl) in the U.S. Under the agreement, Spark Therapeutics will retain regulatory responsibility for obtaining European Medicines Agency approval for investigational voretigene neparvovec.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes